Zobrazeno 1 - 10
of 1 703
pro vyhledávání: '"Advanced prostate cancer"'
Autor:
Fiorella L. Roldan, Ugo Giovanni Falagario, Mats Olsson, Rodolfo Sánchez Salas, Markus Aly, Lars Egevad, Anna Lantz, Henrik Grönberg, Olof Akre, Abolfazl Hosseini, N. Peter Wiklund
Publikováno v:
BJUI Compass, Vol 5, Iss 9, Pp 885-892 (2024)
Abstract Objective The aim of this study is to evaluate treatment patterns and long‐term oncological outcomes of patients with locally advanced prostate cancer (LAPCa). Patients and methods This is a population‐based study including LAPC (cT3‐4
Externí odkaz:
https://doaj.org/article/4b381aec03d14e97aa1cbafc5fe70133
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-5 (2024)
Abstract Background Early diagnosis of prostate cancer is key to achieving a cure and its proper management leads to a good prognosis. In Ghana a large percentage of patients present with advanced disease and unusual presentations in these patients r
Externí odkaz:
https://doaj.org/article/8b2a14a6e183418d8ab4ee34c959415d
Autor:
Tomasz Kucharski, Julita Gmitrzuk, Zuzanna Malinka, Katarzyna Wiśniewska, Anna Jachymek, Martyna Opatowska, Joanna Jakubiec, Marta Piotrowska
Publikováno v:
Quality in Sport, Vol 16 (2024)
Introduction: Prostate cancer is one of the most common malignancies affecting men worldwide, which poses a serious health risk due to its high incidence and impact on quality of life. Despite advances in the diagnosis and treatment of this condition
Externí odkaz:
https://doaj.org/article/d06ae2f235734de3ac19a899faca9fb6
Autor:
Laurence Klotz, Tri Tat
Publikováno v:
BJUI Compass, Vol 5, Iss 3, Pp 392-402 (2024)
Abstract Objective The objective of the study is to evaluate whether low nadir testosterone during treatment with triptorelin pamoate, a luteinising hormone‐releasing hormone (LHRH) agonist, is associated with improved clinical outcomes in patients
Externí odkaz:
https://doaj.org/article/268a0cf19c654584a4c9d127118e9287
Autor:
Chiara Naro, Ambra Antonioni, Vanessa Medici, Cinzia Caggiano, Ariane Jolly, Pierre de la Grange, Pamela Bielli, Maria Paola Paronetto, Claudio Sette
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-18 (2024)
Abstract Background Advanced prostate cancer (PC) is characterized by insensitivity to androgen deprivation therapy and chemotherapy, resulting in poor outcome for most patients. Thus, advanced PC urgently needs novel therapeutic strategies. Mounting
Externí odkaz:
https://doaj.org/article/f52fe4f6963343e09f65b470366db281
Autor:
Allison B. Reiss, Samantha Vasalani, Jacqueline Albert, Wendy Drewes, Kathleen Li, Ankita Srivastava, Joshua De Leon, Aaron E. Katz
Publikováno v:
Medicina, Vol 60, Iss 11, p 1727 (2024)
Androgen deprivation therapy (ADT) is a mainstay treatment for metastatic prostate cancer, improving progression-free survival. ADT suppresses the production of testosterone and reduces circulating levels of the hormone. Luteinizing hormone-releasing
Externí odkaz:
https://doaj.org/article/a9957d3e51954835a0b3ed367cc0a555
Autor:
Kenneth Chen, Ting Hong Wong, Yu Guang Tan, Kae Jack Tay, Wei Chong Tan, Johan Chan, Henry Ho, Christopher Cheng, Jeremy Yuen-Chun Teoh, Peter Ka-Fung Chiu, Hung Jen Wang, Marniza Binti Saad, Ravindran Kanesvaran, You Quan Li, Choon Ta Ng, Jeffrey Kit Loong Tuan, John Shyi Peng Yuen
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Treatment intensification with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPi) have led to improved survival in advanced prostate cancer. However, ADT is linked to significant cardiovascular toxicity, and ARPi also
Externí odkaz:
https://doaj.org/article/8a805922c55f4da38b120190a41e92d7
Publikováno v:
Pakistan Armed Forces Medical Journal, Vol 74, Iss 2 (2024)
ABSTRACT Objectives: To determine the efficacy (achievement of castrate testosterone level at six months) of LHRH agonist therapy with different agonists, i.e., Leuprolide vs. Goserelin. Study Design: Quasi-experimental study. Place and Duratio
Externí odkaz:
https://doaj.org/article/da382f3bf7824e83929d555ddead001a
Autor:
Sabrina Bossio, Lidia Urlandini, Anna Perri, Francesco Conforti, Antonio Aversa, Silvia Di Agostino, Vittoria Rago
Publikováno v:
Life, Vol 14, Iss 9, p 1094 (2024)
Prostate cancer (PCa) is the third highest cause of cancer death in men. PCa is a very heterogeneous tumor form in terms of grade, phenotypes, and genetics, often accompanied by complex networks. PCa is characterized by slow growth that does not comp
Externí odkaz:
https://doaj.org/article/9d24125ed59d4eb39150026cbc823f33
Autor:
Louis Tochukwu Okolie, Ikenna Ifeanyi Nnabugwu, Kevin Ndubuisi Echetabu, Obinna Nnabuife Anikwe, Solomon Kenechukwu Anyimba, Francis Oyiogu Ozoemena
Publikováno v:
African Journal of Urology, Vol 29, Iss 1, Pp 1-7 (2023)
Abstract Background Androgen deprivation therapy (ADT) for advanced prostate cancer (aPCa) causes changes in body mass index (BMI) and in the performance status depending on the extent of cancer remission. The aim of this study is to quantify these c
Externí odkaz:
https://doaj.org/article/35270c2772ba4ae78126d0f52c541685